Potassium Supplements Interactions

Simultaneous administration can produce severe hyperkalemia.

Source: NLP:potassium bicarbonate

Concomitant use can produce severe hyperkalemia. Avoid concomitant use.

Source: NLP:potassium chloride

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic

Potassium supplements can increase the risk of hyperkalemia. Frequent monitoring of serum potassium is recommended if concomitant use is indicated.

Source: NLP:amlodipine besylate and benazepril hydrochloride

Co-administration may result in hyperkalemia. Monitor serum potassium levels in such patients.

Source: NLP:candesartan

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Source: NLP:candesartan cilexetil

Co-administration may result in hyperkalemia. Monitor serum potassium in such patients.

Source: NLP:candesartan cilexetil and hydrochlorothiazide

Risk of significant serum potassium elevation. Should only be given for documented hypokalemia and with caution.

Source: NLP:captopril and hydrochlorothiazide

May lead to significant increases in serum potassium.

Source: NLP:enalapril

Can increase risk of hyperkalemia when combined with fosinopril. Should be used with caution and serum potassium monitored frequently.

Source: NLP:fosinopril

Coadministration may result in hyperkalemia. Monitor serum potassium in such patients.

Source: NLP:fosinopirl sodium

Coadministration with drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. Monitor serum potassium in such patients.

Source: NLP:irbesartan

Potassium supplements may lead to significant hyperkalemia when used with lisinopril which attenuates potassium loss caused by thiazide diuretics.

Source: NLP:lisinopril and hydrochlorothiazide

Concomitant use of losartan and potassium supplements may lead to increases in serum potassium.

Source: NLP:losartan potassium

May lead to increases in serum potassium. Monitoring of serum potassium is advisable.

Source: NLP:olmesartan medoxomil

Increases risk of severe and potentially fatal hyperkalemia, particularly in presence of other risk factors. Avoid use if possible.

Source: NLP:sodium chloride and potassium chloride

Concurrent use increases risk of severe and potentially fatal hyperkalemia, particularly with other hyperkalemia risk factors.

Source: NLP:potassium chloride and dextrose monohydrate

Concurrent use may result in hyperkalemia and cardiac arrhythmias or cardiac arrest.

Source: NLP:potassium iodide

May cause hyperkalemia when used with potassium phosphate. Periodic serum potassium monitoring required.

Source: NLP:potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous

Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.

Source: NLP:potassium phosphates

Increases risk of hyperkalemia. Frequent monitoring of serum potassium recommended if concomitant use indicated.

Source: NLP:ramipril

Concomitant use increases risk of severe and potentially fatal hyperkalemia, especially with other hyperkalemia risk factors. Avoid use; if unavoidable, closely monitor serum potassium.

Source: NLP:sodium chloride, potassium chloride, and calcium chloride

Potassium sparing diuretics increase hyperkalemia risk; avoid use due to potassium content or monitor serum potassium concentrations.

Source: NLP:sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride

Avoid concomitant use due to increased risk of severe and potentially fatal hyperkalemia. If unavoidable, closely monitor serum potassium concentrations.

Source: NLP:dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride

May cause hyperkalemia. Periodic serum potassium level determinations recommended.

Source: NLP:dibasic sodium phosphate, monobasic potassium phosphate and monobasic sodium phosphate

Concomitant administration may lead to severe hyperkalemia. Discontinue potassium supplementation in heart failure patients starting spironolactone.

Source: NLP:spironolactone

Concomitant administration may lead to severe hyperkalemia.

Source: NLP:spironolactone and hydrochlorothiazide

May promote serum potassium accumulation and result in hyperkalemia with triamterene, especially in patients with renal insufficiency.

Source: NLP:triamterene and hydrochlorothiazide

May lead to increases in serum potassium and in heart failure patients to increases in serum creatinine when used with valsartan.

Source: NLP:valsartan and hydrochlorothiazide

ECG changes and hypokalemia from non-potassium-sparing diuretics can be worsened by beta-agonists. Use with caution, especially at higher albuterol doses.

Source: NLP:albuterol sulfate

May lead to increases in serum potassium when combined with valsartan. Monitor serum potassium levels.

Source: NLP:amlodipine and valsartan

Loop or thiazide diuretics can worsen ECG changes and hypokalemia. Caution advised in co-administration.

Source: NLP:arformoterol tartrate inhalation solution

Concomitant use may affect potassium levels. Monitor potassium periodically.

Source: NLP:benazepril hydrochloride and hydrochlorothiazide

Enalapril attenuates potassium loss caused by thiazide diuretics; combined use may increase serum potassium. Monitor potassium levels.

Source: NLP:enalapril maleate

May lead to significant increases in serum potassium when used with enalaprilat. Use with caution and monitor serum potassium frequently.

Source: NLP:enalaprilat

Electrocardiographic changes and hypokalemia may worsen with concomitant beta-agonists.

Source: NLP:fluticasone propionate and salmeterol

ECG changes and hypokalemia from these diuretics can be worsened by formoterol, especially at higher doses. Caution advised.

Source: NLP:formoterol fumarate

ECG changes and hypokalemia from these diuretics can be worsened by formoterol, especially at higher doses. Caution advised.

Source: NLP:formoterol fumarate dihydrate

May increase risk of hyperkalemia with fosinopril sodium and hydrochlorothiazide; concomitant use requires caution and frequent serum potassium monitoring.

Source: NLP:fosinopril sodium and hydrochlorothiazide

β-agonist can acutely worsen ECG changes and hypokalemia induced by diuretics, especially at higher doses. Caution advised.

Source: NLP:ipratropium bromide and albuterol sulfate

Concomitant use with moexipril can increase risk of hyperkalemia. Should be given with caution and patient's serum potassium should be monitored.

Source: NLP:moexipril hydrochloride

Coadministration may result in hyperkalemia. Monitor serum potassium levels.

Source: NLP:olmesartan medoxomil and hydrochlorothiazide

Concurrent use may potentiate the potassium-wasting action of diuretics, requiring monitoring of potassium levels before and during treatment.

Source: NLP:phentermine and topiramate extended-release

May lead to increased serum potassium levels. Monitor potassium during concomitant use.

Source: NLP:sacubitril and valsartan

Non-potassium sparing diuretics may result in ECG changes and hypokalemia that can be worsened by olodaterol. Caution advised in co-administration.

Source: NLP:tiotropium bromide and olodaterol

Concomitant use increases hyperkalemia risk by approximately 1-2%. Serum potassium levels should be monitored.

Source: NLP:tolvaptan

Can increase risk of hyperkalemia when used concomitantly with trandolapril. Use with caution and monitor serum potassium.

Source: NLP:trandolapril